lansoprazole has been researched along with Asthma in 19 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)." | 9.20 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015) |
| "To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER." | 9.16 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012) |
| "Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 9.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
| "The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score." | 6.72 | A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006) |
| "Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)." | 5.20 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015) |
| "Respiratory adverse events from a clinical trial of lansoprazole in children with asthma were analyzed for associations with extensive or poor metabolizer (PM) phenotype based on CYP2C19 haplotypes." | 5.17 | Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. ( Blake, KB; Gong, Y; Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wise, RA, 2013) |
| "We analyzed 306 children between 6 and 17 years of age with poorly controlled asthma enrolled in a 6-month trial assessing lansoprazole for asthma control." | 5.17 | Obesity in children with poorly controlled asthma: Sex differences. ( Dixon, AE; Holbrook, JT; Irvin, CG; Lang, JE; Lima, JJ; Shade, D; Teague, WG; Wei, CY; Wise, RA, 2013) |
| "To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER." | 5.16 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012) |
| "Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 5.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
| " The Genotype Tailored Treatment of Symptomatic Acid Reflux in Children with Uncontrolled Asthma (GenARA) study is a randomized, double-blind, placebo-controlled trial to determine if genotype-tailored PPI dosing improves asthma symptoms among children with inadequately controlled asthma and GERD symptoms." | 2.90 | Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods. ( Blake, KV; Cobbaert, M; Fischer, BM; Franciosi, J; Hossain, MJ; Lang, JE; Lima, JJ; Mougey, EB; Schmidt, S; Tang, M, 2019) |
| "The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score." | 2.72 | A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006) |
| "Gastroesophageal reflux disease (GERD) influences the symptoms of asthma with acid and oxidative stress." | 1.34 | Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. ( Dobashi, K; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Ono, A; Shimizu, Y; Utsugi, M; Yanagitani, N; Zhao, JJ, 2007) |
| "Gastroesophageal reflux disease (GERD) is commonly associated with asthma; however, frequency in nonatopic children with asthmatic symptoms is unknown." | 1.33 | Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006) |
| "The causal association between gastro-oesophageal reflux disease (GERD) and difficult-to-control asthma is unclear." | 1.33 | Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy. ( Chua, CJ; Goh, KL; Liam, CK; Wong, CH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, WT | 1 |
| Li, CY | 1 |
| Chang, YT | 1 |
| Bai, YM | 1 |
| Tsai, SJ | 1 |
| Chen, TJ | 1 |
| Chiou, SH | 1 |
| Chen, MH | 1 |
| Tang, M | 1 |
| Blake, KV | 1 |
| Lima, JJ | 6 |
| Mougey, EB | 3 |
| Franciosi, J | 1 |
| Schmidt, S | 1 |
| Hossain, MJ | 1 |
| Cobbaert, M | 1 |
| Fischer, BM | 1 |
| Lang, JE | 5 |
| Blake, KB | 1 |
| Gong, Y | 1 |
| Holbrook, JT | 5 |
| Wise, RA | 4 |
| Teague, WG | 4 |
| Pierog, AA | 1 |
| Mencin, AA | 1 |
| Wei, CY | 2 |
| Sukhovershin, RA | 1 |
| Ghebremariam, YT | 1 |
| Cooke, JP | 1 |
| Arand, M | 1 |
| Gold, BD | 1 |
| Blake, K | 1 |
| Brown, ED | 1 |
| Castro, M | 1 |
| Dozor, AJ | 1 |
| Mastronarde, JG | 1 |
| Sockrider, MM | 1 |
| Martinez, FD | 1 |
| Dixon, AE | 1 |
| Irvin, CG | 1 |
| Shade, D | 1 |
| Yüksel, H | 1 |
| Yilmaz, O | 1 |
| Kirmaz, C | 1 |
| Aydoğdu, S | 1 |
| Kasirga, E | 1 |
| Littner, MR | 1 |
| Leung, FW | 1 |
| Ballard, ED | 1 |
| Huang, B | 1 |
| Samra, NK | 1 |
| Katz, PO | 1 |
| Wong, CH | 2 |
| Chua, CJ | 1 |
| Liam, CK | 1 |
| Goh, KL | 2 |
| Shimizu, Y | 2 |
| Dobashi, K | 2 |
| Kobayashi, S | 1 |
| Ohki, I | 1 |
| Tokushima, M | 1 |
| Kusano, M | 1 |
| Kawamura, O | 1 |
| Shimoyama, Y | 1 |
| Utsugi, M | 2 |
| Sunaga, N | 1 |
| Ishizuka, T | 2 |
| Mori, M | 2 |
| Sato, A | 1 |
| Tanifuji, Y | 1 |
| Kobayashi, H | 1 |
| Inoue, H | 1 |
| Zhao, JJ | 1 |
| Kawata, T | 1 |
| Ono, A | 1 |
| Yanagitani, N | 1 |
| Kaira, K | 1 |
| Hisada, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III: The Study of Acid Reflux in Children With Asthma[NCT00442013] | Phase 4 | 306 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds (NCT00442013)
Timeframe: Measured at Weeks 0 and 24
| Intervention | mg/mL (Mean) |
|---|---|
| Lansoprazole Group | 2.6 |
| Placebo Group | 2.5 |
ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 0.86 |
| Placebo Group | 0.88 |
Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 5.8 |
| Placebo Group | 6.0 |
Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 1.1 |
| Placebo Group | 1.0 |
A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | Liters (Mean) |
|---|---|
| Lansoprazole Group | 2.2 |
| Placebo Group | 2.3 |
"Episodes of poor asthma control are defined as any one of the following:~2 consecutive days with peak flow at less than 70% of baseline~prescription of oral corticosteroids for asthma~seeking urgent medical care for asthma symptoms~EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks" (NCT00442013)
Timeframe: Measured daily for 24 weeks by diary
| Intervention | number of episodes of poor asthma contrl (Number) |
|---|---|
| Lansoprazole Group | 230 |
| Placebo Group | 184 |
1 review available for lansoprazole and Asthma
| Article | Year |
|---|---|
Gastroesophageal reflux disease and extraesophageal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Mo | 2005 |
7 trials available for lansoprazole and Asthma
| Article | Year |
|---|---|
Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
Topics: Adolescent; Asthma; Body Weights and Measures; Child; Cytochrome P-450 CYP2C19; Double-Blind Method; | 2019 |
Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aryl Hydrocarbon Hydroxylases; Asthma; Bronchit | 2013 |
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
Topics: Adolescent; Asthma; Child; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Gastroesophageal Reflu | 2015 |
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adolescent; Adrenal Cortex Horm | 2012 |
Obesity in children with poorly controlled asthma: Sex differences.
Topics: Adolescent; Asthma; Body Mass Index; Child; Cohort Studies; Female; Forced Expiratory Volume; Humans | 2013 |
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adrenal Cortex Hormones; Adult; | 2005 |
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Asthma; Drug Evaluation; | 2006 |
11 other studies available for lansoprazole and Asthma
| Article | Year |
|---|---|
Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study.
Topics: Asthma; Case-Control Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Proton Pump Inhibito | 2023 |
A childhood case of eosinophilic gastritis and protein-losing enteropathy.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Asthma; Child, Preschool; Cromol | 2014 |
Lansoprazole worsens asthma control in poor metabolizers: is nitric oxide involved?
Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra | 2015 |
Reply: worsening asthma control in children taking lansoprazole: possible mechanisms.
Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra | 2015 |
[Nocturnal shortness of breath: in asthma look for reflux -- is it worthwhile?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Bronchodilator Agents; Gastroesophageal Reflux; Hum | 2008 |
Children, asthma, and proton pump inhibitors: costs and perils of therapeutic creep.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Enzyme Inhibitors; Female; Humans; Lansoprazole; Ma | 2012 |
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Ch | 2006 |
Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Asthma; Cohort Studies; Female; Forced Expiratory | 2006 |
[Effects of proton pump inhibitor on airway hyperresponsiveness in asthmatics with gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Female; Gastroesophageal Reflux; | 2006 |
The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans; | 2006 |
Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Biomarkers; Breath Tests; Comorbidity; Dinoprost; F | 2007 |